Novolytics is a biotechnology company focused on addressing antimicrobial resistance through the development of innovative bacteriophage therapies. Utilizing advanced phage technology, Novolytics aims to create effective treatments for bacterial infections that are increasingly resistant to traditional antibiotics. The company leverages its expertise in phage science to design targeted solutions that can either work alone or in conjunction with existing antimicrobial treatments.